Senate Bill 1052
115th Congress(2017-2018)
BENEFIT Act of 2017
Active
Active
Passed Senate on Aug 3, 2017
Overview
Text
Introduced
May 4, 2017
Latest Action
Aug 11, 2017
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1052
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Mississippi
Minnesota
Passed
August 3, 2017
Type
Unanimous Consent
Unanimous Consent
A senator may request unanimous consent on the floor to set aside a specified rule of procedure so as to expedite proceedings. If no Senator objects, the Senate permits the action, but if any one senator objects, the request is rejected. Unanimous consent requests with only immediate effects are routinely granted, but ones affecting the floor schedule, the conditions of considering a bill or other business, or the rights of other senators, are normally not offered, or a floor leader will object to it, until all senators concerned have had an opportunity to inform the leaders that they find it acceptable.
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S4788)
Summary

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2017 or the BENEFIT Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to consider patient-focused drug development data, such as patient preferences, patient-reported outcomes, and patient experiences, as part of the risk-benefit assessment of new drugs. Following approval of a drug, the FDA must include a description of how this information was considered in its statement of patient experience.
Text (3)
August 4, 2017
August 3, 2017
Actions (10)
08/11/2017
Referred to the Subcommittee on Health.
08/04/2017
Referred to the House Committee on Energy and Commerce.
08/04/2017
Received in the House.
08/03/2017
Message on Senate action sent to the House.
08/03/2017
Passed Senate without amendment by Unanimous Consent. (text: CR S4788)
08/03/2017
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S4788)
08/03/2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S4787-4788)
08/03/2017
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S4787-4788)
05/04/2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
05/04/2017
Introduced in Senate
Public Record
Created
May 5, 2017 12:41:44 AM
Updated
Feb 1, 2021 10:22:00 PM